Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Other Working Capital Changes (2016 - 2025)

Dexcom (DXCM) has disclosed Other Working Capital Changes for 16 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes rose 186.25% to $6.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.8 million, a 155.17% increase, with the full-year FY2025 number at $14.8 million, up 155.17% from a year prior.
  • Other Working Capital Changes was $6.9 million for Q4 2025 at Dexcom, up from $2.4 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $97.9 million in Q1 2022 to a low of -$31.6 million in Q3 2024.
  • A 5-year average of $7.7 million and a median of $550000.0 in 2022 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: skyrocketed 1525.81% in 2022, then tumbled 1176.92% in 2023.
  • Dexcom's Other Working Capital Changes stood at $3.1 million in 2021, then surged by 1525.81% to $50.4 million in 2022, then plummeted by 112.1% to -$6.1 million in 2023, then crashed by 31.15% to -$8.0 million in 2024, then surged by 186.25% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Other Working Capital Changes are $6.9 million (Q4 2025), $2.4 million (Q3 2025), and $22.0 million (Q2 2025).